GH Research PLC (GHRS)
NasdaqGM · USD · Healthcare · Biotechnology
$19.59 (+2.14%) as of
Key statistics
- Market cap
- 1.34B
- Forward P/E
- -10.59
- EPS (TTM)
- -1.05
- Dividend yield
- 0.00%
- 52-week range
- 12.04 – 31.44
- Beta
- 1.33
- Profit margin
- 0.00%
- Analyst target
- $42.89
- Volume
- 13.24k
About GH Research PLC
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Dublin, Ireland
- Employees
- 73
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.